Preliminary evidence demonstrates efficacy against meningiomas, which varies by grade with PFS-6 rates of 94%, 48%, and 0% in Grade 1, 2, and 3 SSTR2-positive meningiomas, respectively [49,135]. The gene discussed is SSTR2; the disease is meningioma.